Prostate cancer in renal transplant recipients

Abstract

Our results showed that RTR are at risk for early occurrence and for locally advanced prostate cancer, especially when they received a CNI and AZA maintenance immunosuppressive therapy.

Prostate carcinoma in liver transplant recipients: Think about it!

“…Diagnoses were made earlier in life, at approximately 60 years of age [18]. Such data should justify proposing a PC screening to solid organ transplant recipients.…”

“…However, no evidence suggests a specific effect on prostate carcinoma. Only 1 study demonstrated potential carcinologic effects of CINinhibitor and azathioprine on the prostate [18]. It is therefore difficult to recommend any immunosuppressive regimen modifications after PC diagnosis.…”

Prostate-specific antigen screening and prostate cancer treatment in renal transplantation candidates: A survey of U.S. transplantation centers

“…There has been some suggestion that immunosuppression can affect the natural history of CaP. Kleinclauss et al [9] reported a high rate of T3/4 disease (36%) and metastasis (19.3%) at presentation in renal transplantation patients and that addition of azathioprine to calcineurin inhibitors was the only independent risk factor for higher-stage disease. Another recent study showed an increased incidence of CaP in renal transplantation patients who were treated with sirolimus when compared with that in those treated with other therapies.…”

Modifications to Facilitate Extraperitoneal Robot-Assisted Radical Prostatectomy Post Kidney Transplant

“…A recent study highlighted that prostate cancer appears sooner, with a higher rate of advanced or metastatic disease in RTR than in the general population. 20 …”